What Is VIP? Research Evidence & Profile

What Is Vasoactive Intestinal Peptide (VIP)?

Vasoactive Intestinal Peptide (VIP) is a peptide identified by the established Vasoactive Intestinal Peptide and VIP names. This page identifies the material as VIP (Vasoactive Intestinal Peptide). The Vasoactive Intestinal Peptide (VIP) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

315ClinicalTrials.gov query records

43485PubMed query records

6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for Vasoactive Intestinal Peptide (VIP) is organized around VIP receptor research, neuropeptide signaling literature, ligand-response studies, and analytical peptide workflows. For Vasoactive Intestinal Peptide (VIP), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
NCT04453839ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)	Not stated	No Longer Available	Critical COVID-19 With Respiratory Failure	2023-02-03
NCT05785975Effectiveness of Modified Integrated Colorectal Cancer Screening System in Saudi Arabia	NA	Unknown	Colorectal Cancer, Colorectal Neoplasms	2023-06-26
NCT06417424Observe Intestinal Tract Cleaness of Senile Constipation Patients Used Gastrointestinal External Stimulation	NA	Unknown	Electric Stimulation	2024-05-16
NCT05918172Comparison of the Frequency of Ventilator-Associated Pneumonia in Intubated Patients Followed Up With Automatic Cuff Pressure Controller and Manual Cuff Pressure Controller in Pediatric Intensive Care	Not stated	Completed	Ventilator-associated Pneumonia	2026-03-17
NCT05803421A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk	Phase 3	Completed	Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease	2026-04-17
NCT02591212A Pilot of Bystander Training Programming in Sexual Violence and Subtance Abuse	NA	Completed	Sexual Violence	2016-10-26

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

VIP regulation of embryonic growth.

Annals of the New York Academy of Sciences · 1996 Dec 26

PMID 8993408

Selected PubMed record

VIP: molecular biology and neurobiological function.

Molecular neurobiology · 1989 Winter

PMID 2698176

Selected PubMed record

VIP as a trophic factor in the CNS and cancer cells.

Peptides · 2003 Jan

PMID 12576099

Selected PubMed record

VIP Modulation of Hippocampal Synaptic Plasticity: A Role for VIP Receptors as Therapeutic Targets in Cognitive Decline and Mesial Temporal Lobe Epilepsy.

Frontiers in cellular neuroscience · 2020

PMID 32595454

Selected PubMed record

Vegetative Insecticidal Protein (Vip): A Potential Contender From Bacillus thuringiensis for Efficient Management of Various Detrimental Agricultural Pests.

Frontiers in microbiology · 2021

PMID 34054756

Selected PubMed record

Intercellular communication mediated by VIP in the cerebral cortex.

Peptides · 1986

PMID 2875443

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: VIP (Vasoactive Intestinal Peptide)
Available Specifications: 5mg, 10mg
Pack Format: 10 Vials

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: NOVABIO product identity record · No single PubChem record is asserted for this catalogue entry.

Research Tools for Vasoactive Intestinal Peptide (VIP)

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Vasoactive Intestinal Peptide (VIP) Research Summary

Identity

VIP (Vasoactive Intestinal Peptide); specifications: 5mg, 10mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

Evidence

315 registry records and 43485 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Vasoactive Intestinal Peptide (VIP) is represented here by the catalogue identity VIP (Vasoactive Intestinal Peptide). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 5mg, 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for Vasoactive Intestinal Peptide (VIP) is organized around VIP receptor research, neuropeptide signaling literature, ligand-response studies, and analytical peptide workflows. For Vasoactive Intestinal Peptide (VIP), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 315 ClinicalTrials.gov records and 43485 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Vasoactive Intestinal Peptide (VIP) FAQ

What is Vasoactive Intestinal Peptide (VIP)?

What research records are indexed for Vasoactive Intestinal Peptide (VIP)?

The synchronized query returned 315 ClinicalTrials.gov records and 43485 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Vasoactive Intestinal Peptide (VIP) FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.